epocrates, an athenahealth, Inc. company that delivers digital clinical decision support to prescribers, shared its commitment to accelerate the company’s fast-growing commercial business and further invest in and innovate its commercial product offerings, following a period of tremendous change in the pharmaceutical industry. To help enhance and broaden epocrates’ services, the company has recently brought on Matt Titus, an industry veteran of 13 years, to serve as the organization’s vice president, chief commercial officer.
“In recent years, we have seen massive shifts in the pharmaceutical industry, especially within the marketing vertical. From the decrease of in-person meetings to the onset of AI transforming marketing campaigns, the way our commercial clients are working is different and more digital than ever before. This year, we expect the power and potential of machine learning to increase, the utilization of non-personal promotion to become more critical, and the need for meaningful engagement with clinicians at critical moments to grow...” said Diane Bartoli, vice president and general manager, epocrates. “With years of highly relevant sales and business development executive leadership experience, Matt is an invaluable addition to our team, helping us expand our commercial success and pivot with these massive industry shifts for the benefit of our clients.”
Titus joins epocrates from Real Chemistry, a global health innovation company, where he served as EVP, sales & customer experience.
“I’m honored to join the epocrates team and help our clients share their important messages with our nation’s providers to, in turn, help them stay ‘in the know’ about the latest treatment options,” said Titus. “I look forward to innovating in new ways that will address evolving client needs and help drive meaningful and significant results.”
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.